Conclusion: The overall analysis including all trials showed that supplements provided moderate and clinically meaningful treatment effects on pain and function in patients with hand, hip or knee osteoarthritis at short term, although the quality of evidence was very low. Some supplements with a limited number of studies and participants suggested large treatment effects, while widely used supplements such as glucosamine and chondroitin were either ineffective or showed small and arguably clinically unimportant treatment effects. Supplements had no clinically important effects on pain and function at medi
PubMed 29018060 ↗Boswellia
The short answer. More people than not who report on Boswellia say it helped (59% of 22). It is most often used for pain & inflammation: 82% of 17 reports say that improved. It is well studied — 35 meta-analyses on PubMed.
From 48 mentions in total — the rest didn't say how it went and aren't counted.
What Boswellia does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 35 meta-analyses on PubMed ↗ · 78 randomized trials ↗
Conclusion: Based on current evidence, Boswellia and its extract may be an effective and safe treatment option for patient with OA, and the recommended duration of treatment with Boswellia and its extract is at least 4 weeks.
PubMed 32680575 ↗Conclusion: However, several limitations relate to clinical research on Ayurveda. Well-planned, well-conducted and well-published trials are warranted to improve the evidence for Ayurvedic interventions.
PubMed 25062981 ↗Conclusion: These results suggest that certain supplements may be useful as part of non-pharmacological KOA management. However, further large-scale, well-designed randomized controlled trials (RCTs) are needed to confirm these findings, particularly those that include more standardized dosages and formulations, as well as to evaluate their long-term efficacy.
PubMed 40806131 ↗60 human trials on ClinicalTrials.gov test Boswellia — 39 completed, 3 recruiting now. See all on ClinicalTrials.gov ↗
- Clinical Evaluation of the Efficacy and Safety of a Medical Device in the Form of Rectal Suppositories (Prospidol®) for the Treatment of Symptoms Associated With Chronic Prostatitis/Chronic Pelvic Pain Syndrome. · Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) · 2026
- Frankincense and Herbal Extracts for Plaque-Induced Gingivitis: A Double-Blind RCT · Gingivitis · 2026
- Efficacy of Bioactive Collagen Peptide Compared to Glucosamine and Chondroitin Sulphate in Grade I-III Knee Osteoarthritis · Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3) · 2025
Reports to the FDA
Adverse-event reports about supplements containing it, submitted to the US FDA by consumers and doctors.
24 reports name a product containing Boswellia (2014–2025); 12 involved hospitalization or worse. Most often reported:
- Pruritus · 4
- Rash · 4
- Abdominal pain · 3
- Choking · 2
- Arthropathy · 2
- Osteoarthritis · 2
A report doesn't prove the supplement caused the problem — many products contain several ingredients, and these counts can't tell you how often it happens. Source: FDA CAERS ↗ · raw reports (openFDA) ↗.
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
2 recalls of products named for Boswellia. Most recent:
- 2025-12-31 · Class II: Unapproved drug claims on product labeling and product misbranded due to no Supplement Facts label record ↗
- 2018-08-22 · Class III: Product contains undeclared ingredients, Hydroxypropyl Methylcellulose (HPMC), Titanium Dioxide, Polyethylene Glycol (PEG), Triacetin. record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
“Boswellia is likely to be safe when taken orally. Boswellia serrata extract in doses up to 1,000 mg daily has been safely used in several clinical trials lasting up to 6 months.” NCCIH ↗
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“take curcumin, lots of fish oil, boswellia and devil's claw. I tried every supplement and combination. These worked best for me.”
“I have tried a LOT of supplements (glucosamin, chondroitin, MSM, boron, boswellia, serrapeptase, turmeric, fish oil, D3, K2, celadrin...) and nothing helps”
“Boswellia is great! It's helped a ton with my joint problems.”
“Boswellia and Cissus pretty much changed my life. Would highly recommend”
Top discussions (5)
- How to prevent/protect more joint/tendon damage ↗
- Joint pain relief for my mom? Sam-e? ↗
- If turmeric/curcumin worked, do I need to take it forever? ↗
- Our lungs might be declining quietly even if we’ve never smoked!! ↗
- In my late 70s and I've been helping my son take care of his 1 year old. My shoulders aren't what it used to be and the pain is getting worst from carrying the baby overtime. Would NR (nicotinamide riboside - niagen) help due to its research claims of delaying aging? ↗
Other options for pain & inflammation
Sources
- User reports: 48 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA recalls ↗
- NCCIH (NIH) ↗
- US Food and Drug Administration: CAERS adverse-event reports ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate